Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00061022 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,200
- Enrollment target
NCT00061022 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 3,200 participants.
The verdict
NCT00061022, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,200 participants
- Enrollment target
Study Summary
This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.
Interventions
- DRUG NXY-059
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,200 participants |
| Start Date | 2003-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00061022
The ClinicalTrials.gov registry entry for NCT00061022 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NXY-059 is the first listed.
NCT00061022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00061022 about?
NCT00061022 is a clinical study titled "Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke". This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.
What is the current status of trial NCT00061022?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,200 participants. The study started on 2003-05. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00061022?
The interventions under investigation include: NXY-059 (DRUG).
Who is sponsoring clinical trial NCT00061022?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.